循環腫瘍細胞（CTC）の市場規模、シェア、動向分析レポート：用途別、検体別、製品別、技術別、最終用途別、地域別、セグメント予測、2025年～2030年

循環腫瘍細胞（CTC）市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の循環腫瘍細胞（CTC）市場規模は、2025年から2030年にかけてCAGR 12.2％で拡大し、2030年には249億6,000万米ドルに達すると推定されています。

この背景には、世界のがん有病率の上昇、非侵襲的がん診断ツールに対する需要の増加、循環腫瘍細胞（CTC）技術の進歩があります。

近年、CTCは、がんの予後を判定し、臨床医ががん治療に必要な治療法の種類を決定するためにますます使用されるようになっています。CTCは、がんの早期発見、がん再発のリスク評価、治療の指針、がん治療中の患者の継続的なモニタリングなど、がん管理のさまざまな分野で幅広く応用されています。がんの診断やモニタリングに使用できるCTCを利用した様々な腫瘍マーカーの開発は、予測期間中にCTCの採用を促進すると予想されます。したがって、がん患者の末梢血におけるCTCの検出は、有望な診断ツールとして機能すると結論づけることができます。例えば、CTCの定量化とゲノム・プロファイリングは、前立腺がんの費用対効果が高く正確な非侵襲的モニタリングを可能にします。CTCの検出はがん患者の生存を予測します。

希少がんではこれらの細胞の適用範囲が限られているため、収益の伸びはある程度妨げられています。循環腫瘍細胞（CTC）は、神経原性がんのようなEpCAM陰性または低発現を特徴とする腫瘍には適用できないです。例えば、肉腫に対する循環腫瘍細胞（CTC）の特徴を示す証拠はほとんどないです。逆に、上皮抗原を標的とした抗体を用いた方法など、これらの細胞を単離するための多くの方法が研究されており、近い将来これらの課題が克服されることが期待されています。

しかし、近年、バリューチェーンの形成とCTC市場の成長を加速させるため、大手企業による買収や製薬企業との数多くの提携による技術の一元化が相次ぎ、実用化が推進されています。例えば、ワシントン大学医学部は2023年6月、転移がんが血液中に排出する腫瘍細胞を検出する新規検査法を開発するため、シアトルに本社を置くバイオテクノロジー企業RareCyte社と提携しました。また、調査によると、血流中の循環腫瘍細胞（CTC）を把握することで、腫瘍細胞の変化を追跡することができ、治療の最適化が可能になるといいます。

循環腫瘍細胞（CTC）市場レポートハイライト

• 技術別では、CTC濃縮・分離のための製品の利用可能性の増加、世界中で高い利用率と製品の浸透により、CTC検出・濃縮法分野が2024年に40.92%の最大売上シェアを占めました。
• CTC分析は、治験研究、医薬品開発、バイオマーカー研究への応用の可能性が高まっているため、予測期間中に最も速いCAGRを記録する見込みです。
• 用途別では、調査セグメントが2024年の市場を独占し、2025年から2030年にかけて最も速いCAGRを記録すると予測されています。
• 製品別では、キット・試薬が2024年に市場を席巻し、2025～2030年の予測期間で最も速い成長が見込まれています。
• 検体別では、血液セグメントが2024年に市場を席巻しました。その他の体液セグメントは2025年から2030年にかけて最も速いCAGRが見込まれます。
• 最終用途別では、がん診断・治療のための研究開発活動への注目が高まっていることから、研究・学術機関セグメントが2024年の市場を独占しました。
• 北米が2024年にCTC市場を独占したのは、主要市場プレイヤーのBio-Techne Corporation、Precision Medicine Group LLC、Epic Sciences、APPLIED DNA SCIENCES, INC.、LungLife AI, Inc.の存在や、この地域における製薬・バイオテクノロジー研究部門の成長などの要因によるものです。
• アジア太平洋地域は、日本のような国々でプレゼンスを拡大している複数の企業により、予測期間中に最も速いCAGRを記録すると予想されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 循環腫瘍細胞（CTC）市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 循環腫瘍細胞（CTC）市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 循環腫瘍細胞（CTC）市場：技術別推定・動向分析

• テクノロジーセグメントダッシュボード
• 世界の循環腫瘍細胞（CTC）市場の技術変動分析
• 循環腫瘍細胞（CTC）の世界市場規模と動向分析（技術別、2018～2030年）
• 2018年から2030年までの市場規模と予測および動向分析
  • CTC検出および濃縮法
  • CTC直接検出法
  • CTC分析

第5章 循環腫瘍細胞（CTC）市場：用途別推定・動向分析

• 用途セグメントダッシュボード
• 世界の循環腫瘍細胞（CTC）市場の用途変動分析
• 循環腫瘍細胞（CTC）の世界市場規模と動向分析（用途別、2018～2030年）
• 2018年から2030年までの市場規模と予測および動向分析
  • 臨床
  • 調査

第6章 循環腫瘍細胞（CTC）市場：製品別推定・動向分析

• 製品セグメントダッシュボード
• 世界の循環腫瘍細胞（CTC）市場の製品変動分析
• 循環腫瘍細胞（CTC）の世界市場規模と動向分析（製品別、2018～2030年）
• 2018年から2030年までの市場規模と予測および動向分析
  • キットと試薬
  • 採血管
  • デバイスまたはシステム

第7章 循環腫瘍細胞（CTC）市場：検体別推定・動向分析

• 検体セグメントダッシュボード
• 世界の循環腫瘍細胞（CTC）市場の検体変動分析
• 循環腫瘍細胞（CTC）の世界市場規模と動向分析（検体別、2018～2030年）
• 2018年から2030年までの市場規模と予測および動向分析
  • 血
  • 骨髄
  • その他の体液

第8章 循環腫瘍細胞（CTC）市場：最終用途別推定・動向分析

• 最終用途セグメントダッシュボード
• 世界の循環腫瘍細胞（CTC）市場の最終用途変動分析
• 循環腫瘍細胞（CTC）の世界市場規模と動向分析（最終用途別、2018～2030年）
• 2018年から2030年までの市場規模と予測および動向分析
  • 調査・学術機関
  • 病院と診療所
  • 診断センター

第9章 循環腫瘍細胞（CTC）市場：地域別推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業のポジション分析（2024年）
  • QIAGEN
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC.
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Cell Microsystems
  • Greiner Bio One International GmbH
  • Ikonisys Inc.
  • Miltenyi Biotec
  • Creative Bioarray
  • BioFluidica
  • Abnova Corporation
  • Biolidics Limited
  • Creativ MicroTech, Inc.
  • LungLife AI
  • Epic Sciences
  • Rarecells Diagnostics
  • ScreenCell
  • Menarini Silicon Biosystems
  • APPLIED DNA SCIENCES, INC.
  • Sysmex Corporation
  • STEMCELL Technologies, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
• Table 3 North America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 4 North America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 5 North America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 6 North America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 7 North America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 8 U.S. circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 9 U.S. circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 10 U.S. circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 11 U.S. circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 12 U.S. circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 13 Canada circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 14 Canada circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 15 Canada circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 16 Canada circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 17 Canada circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 18 Mexico circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 19 Mexico circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 20 Mexico circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 21 Mexico circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 22 Mexico circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 23 Europe circulating tumor cells market, by region, 2018 - 2030 (USD Million)
• Table 24 Europe circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 25 Europe circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 26 Europe circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 27 Europe circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 28 Europe circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 29 UK circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 30 UK circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 31 UK circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 32 UK circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 33 UK circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 34 Germany circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 35 Germany circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 36 Germany circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 37 Germany circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 38 Germany circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 39 Italy circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 40 Italy circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 41 Italy circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 42 Italy circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 43 Italy circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 44 France circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 45 France circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 46 France circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 47 France circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 48 France circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 49 Spain circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 50 Spain circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 51 Spain circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 52 Spain circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 53 Spain circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 54 Sweden circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 55 Sweden circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 56 Sweden circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 57 Sweden circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 58 Sweden circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 59 Denmark circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 60 Denmark circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 61 Denmark circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 62 Denmark circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 63 Denmark circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 64 Norway circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 65 Norway circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 66 Norway circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 67 Norway circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 68 Norway circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 69 Asia Pacific circulating tumor cells market, by region, 2018 - 2030 (USD Million)
• Table 70 Asia Pacific circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 71 Asia Pacific circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 72 Asia Pacific circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 73 Asia Pacific circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 74 Asia Pacific circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 75 China circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 76 China circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 77 China circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 78 China circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 79 China circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 80 Japan circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 81 Japan circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 82 Japan circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 83 Japan circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 84 Japan circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 85 India circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 86 India circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 87 India circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 88 India circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 89 India circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 90 South Korea circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 91 South Korea circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 92 South Korea circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 93 South Korea circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 94 South Korea circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 95 Australia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 96 Australia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 97 Australia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 98 Australia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 99 Australia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 100 Thailand circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 101 Thailand circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 102 Thailand circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 103 Thailand circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 104 Thailand circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 105 Latin America circulating tumor cells market, by region, 2018 - 2030 (USD Million)
• Table 106 Latin America circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 107 Latin America circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 108 Latin America circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 109 Latin America circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 110 Latin America circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 111 Brazil circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 112 Brazil circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 113 Brazill circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 114 Brazil circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 115 Brazil circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 116 Argentina circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 117 Argentina circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 118 Argentina circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 119 Argentina circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 120 Argentina circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 121 Middle East Africa circulating tumor cells market, by region, 2018 - 2030 (USD Million)
• Table 122 Middle East Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 123 Middle East Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 124 Middle East Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 125 Middle East Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 126 Middle East Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 127 South Africa circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 128 South Africa circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 129 South Africa circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 130 South Africa circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 131 South Africa circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 132 Saudi Arabia circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 133 Saudi Arabia circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 134 Saudi Arabia circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 135 Saudi Arabia circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 136 Saudi Arabia circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 137 UAE circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 138 UAE circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 139 UAE circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 140 UAE circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 141 UAE circulating tumor cells market, by end use, 2018 - 2030 (USD Million)
• Table 142 Kuwait circulating tumor cells market, by technology, 2018 - 2030 (USD Million)
• Table 143 Kuwait circulating tumor cells market, by application, 2018 - 2030 (USD Million)
• Table 144 Kuwait circulating tumor cells market, by product, 2018 - 2030 (USD Million)
• Table 145 Kuwait circulating tumor cells market, by specimen, 2018 - 2030 (USD Million)
• Table 146 Kuwait circulating tumor cells market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Circulating tumor cells market: market outlook
• Fig. 9 Circulating tumor cells competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Circulating tumor cells market driver impact
• Fig. 15 Circulating tumor cells market restraint impact
• Fig. 16 Circulating tumor cells market strategic initiatives analysis
• Fig. 17 Circulating tumor cells market: Technology movement analysis
• Fig. 18 Circulating tumor cells market: Technology outlook and key takeaways
• Fig. 19 CTC detection & enrichment methods market estimates and forecast, 2018 - 2030
• Fig. 20 Immunocapture (label-based) estimates and forecast, 2018 - 2030
• Fig. 21 Positive selection market estimates and forecast, 2018 - 2030
• Fig. 22 Negative selection estimates and forecast, 2018 - 2030
• Fig. 23 Size-based separation (label-free) market estimates and forecast, 2018 - 2030
• Fig. 24 Membrane-based estimates and forecast, 2018 - 2030
• Fig. 25 Microfluidic-based estimates and forecast, 2018 - 2030
• Fig. 26 Density-based Separation (Label-free) estimates and forecast, 2018 - 2030
• Fig. 27 Combined Methods estimates and forecast, 2018 - 2030
• Fig. 28 CTC direct detection methods estimates and forecast, 2018 - 2030
• Fig. 29 SERS estimates and forecast, 2018 - 2030
• Fig. 30 Microscopy estimates and forecast, 2018 - 2030
• Fig. 31 Others estimates and forecast, 2018 - 2030
• Fig. 32 CTC Analysis estimates and forecast, 2018 - 2030
• Fig. 33 Circulating tumor cells Market: Application movement Analysis
• Fig. 34 Circulating tumor cells market: Application outlook and key takeaways
• Fig. 35 Clinical/ Liquid Biopsy market estimates and forecasts, 2018 - 2030
• Fig. 36 Risk Assessment market estimates and forecasts, 2018 - 2030
• Fig. 37 Screening and Monitoring market estimates and forecasts, 2018 - 2030
• Fig. 38 Research market estimates and forecasts, 2018 - 2030
• Fig. 39 Cancer Stem Cell & Tumorogenesis Research market estimates and forecasts, 2018 - 2030
• Fig. 40 Drug/Therapy Development market estimates and forecasts, 2018 - 2030
• Fig. 41 Circulating tumor cells Market: Product movement Analysis
• Fig. 42 Circulating tumor cells market: Product outlook and key takeaways
• Fig. 43 Kits & reagents market estimates and forecasts, 2018 - 2030
• Fig. 44 Blood collection tubes market estimates and forecasts, 2018 - 2030
• Fig. 45 Devices or Systems market estimates and forecasts, 2018 - 2030
• Fig. 46 Circulating tumor cells Market: Specimen movement Analysis
• Fig. 47 Circulating tumor cells market: Specimen outlook and key takeaways
• Fig. 48 Blood market estimates and forecasts, 2018 - 2030
• Fig. 49 Bone marrow market estimates and forecasts, 2018 - 2030
• Fig. 50 Other body fluids market estimates and forecasts, 2018 - 2030
• Fig. 51 Circulating tumor cells Market: End use movement Analysis
• Fig. 52 Circulating tumor cells market: End use outlook and key takeaways
• Fig. 53 Research and academic institutes market estimates and forecasts, 2018 - 2030
• Fig. 54 Hospital and clinics market estimates and forecasts, 2018 - 2030
• Fig. 55 Diagnostic centers market estimates and forecasts, 2018 - 2030
• Fig. 56 Global circulating tumor cells market: Regional movement analysis
• Fig. 57 Global circulating tumor cells market: Regional outlook and key takeaways
• Fig. 58 North America, by country
• Fig. 59 North America
• Fig. 60 North America market estimates and forecasts, 2018 - 2030
• Fig. 61 U.S. country dynamics
• Fig. 62 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 63 Canada country dynamics
• Fig. 64 Canada market estimates and forecasts, 2018 - 2030
• Fig. 65 Mexico country dynamics
• Fig. 66 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 67 Europe market estimates and forecasts, 2018 - 2030
• Fig. 68 UK country dynamics
• Fig. 69 UK market estimates and forecasts, 2018 - 2030
• Fig. 70 Germany country dynamics
• Fig. 71 Germany market estimates and forecasts, 2018 - 2030
• Fig. 72 France country dynamics
• Fig. 73 France market estimates and forecasts, 2018 - 2030
• Fig. 74 Italy country dynamics
• Fig. 75 Italy market estimates and forecasts, 2018 - 2030
• Fig. 76 Spain country dynamics
• Fig. 77 Spain market estimates and forecasts, 2018 - 2030
• Fig. 78 Denmark country dynamics
• Fig. 79 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 80 Sweden country dynamics
• Fig. 81 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 82 Norway country dynamics
• Fig. 83 Norway market estimates and forecasts, 2018 - 2030
• Fig. 84 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 85 China country dynamics
• Fig. 86 China market estimates and forecasts, 2018 - 2030
• Fig. 87 Japan country dynamics
• Fig. 88 Japan market estimates and forecasts, 2018 - 2030
• Fig. 89 India country dynamics
• Fig. 90 India market estimates and forecasts, 2018 - 2030
• Fig. 91 Thailand country dynamics
• Fig. 92 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 93 South Korea country dynamics
• Fig. 94 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 95 Australia country dynamics
• Fig. 96 Australia market estimates and forecasts, 2018 - 2030
• Fig. 97 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 98 Brazil country dynamics
• Fig. 99 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 100 Argentina country dynamics
• Fig. 101 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 102 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 103 South Africa country dynamics
• Fig. 104 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 105 Saudi Arabia country dynamics
• Fig. 106 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 107 UAE country dynamics
• Fig. 108 UAE market estimates and forecasts, 2018 - 2030
• Fig. 109 Kuwait country dynamics
• Fig. 110 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 111 Market position of key market players- Circulating tumor cells market

Circulating Tumor Cells Market Growth & Trends:

The global circulating tumor cells market size is estimated to reach USD 24.96 billion by 2030, expanding at a CAGR of 12.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. This is attributed to rising prevalence of cancer worldwide, increasing demand for non-invasive cancer diagnostic tools, and advancements in circulating tumor cells (CTC) technologies.

In recent years, CTCs are increasingly used for determining the prognosis of cancer and helping clinicians decide the type of therapy required for cancer treatment. CTCs have wide applications in several areas of cancer management-early detection of cancer, risk assessment of cancer recurrence, guidance for therapies, and continuous monitoring of a patient during cancer treatment. The development of various tumor markers utilizing CTCs, which can be used to diagnose or monitor cancer, is expected to boost the adoption of CTCs over the forecast period. Therefore, it can be concluded that the detection of CTCs in the peripheral blood of patients with cancer acts as a promising diagnostic tool. For instance, quantitation and genomic profiling of CTCs enables cost-effective & accurate noninvasive monitoring of prostate cancer. The detection of CTCs is predictive for survival of cancer patients.

The limited applicability of these cells in rare cancers has hampered revenue growth to a certain extent. Circulating tumor cells are not applicable to tumors characterized by EpCAM negativity or low expression, such as neurogenic cancers. For instance, there is negligible evidence for the characterization of circulating tumor cells for sarcoma. Conversely, numerous methods are being studied for the isolation of these cells, which include methods based on epithelial antigen-targeted antibodies, anticipating to overcome these challenges in the near future.

However, in recent years, there has been a push for practical application, largely as a result of a wave of large players centralizing the technology through acquisitions and numerous partnerships with pharmaceutical firms to advance the formation of a value chain and speed up the CTC market's growth. For instance, in June 2023, to develop a novel test for the detection of tumor cells that metastatic cancers shed into the blood, the University of Washington School of Medicine collaborated with RareCyte, Inc., which is a biotech company headquartered in Seattle. In addition, according to the research, the understanding of the circulating tumor cells in the bloodstream can track the changes in tumor cells, thus optimizing the treatment.

Circulating Tumor Cells Market Report Highlights:

• Based on technology, The CTC detection and enrichment methods segment accounted for the largest revenue share of 40.92% in 2024 owing to the increased availability of products for CTC enrichment and isolation as well as high usage and product penetration across the globe
• CTC analysis is expected to register the fastest CAGR during the forecast period due to the growing application potential of CTC analysis for investigational research, drug development, and biomarker studies
• Based on application, the research segment dominated the market in 2024 and it is expected to witness the fastest CAGR from 2025 to 2030
• Kits & reagent dominated the product segment in 2024, and it is expected to witness the fastest growth in forecast period of 2025-2030
• Based on specimen, the blood segment dominated the market in 2024. The other body fluids segment is expected to witness the fastest CAGR from 2025 to 2030
• Based on end-use, the research & academic institutes segment dominated the market in 2024 due to increasing focus on research and development activities for cancer diagnosis and treatment
• North America dominated the CTC market in 2024, owing to factors such as the presence of key market players Bio-Techne Corporation, Precision Medicine Group LLC, Epic Sciences, APPLIED DNA SCIENCES, INC., and LungLife AI, Inc. and the growth in pharmaceutical & biotechnology research sectors in this region
• Asia Pacific is expected to register the fastest CAGR over the forecast period due to several companies expanding their presence in countries like Japan

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Application
  • 1.2.3. Product
  • 1.2.4. Specimen
  • 1.2.5. End use
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Circulating Tumor Cells Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Advancements in chip technology
    • 3.2.1.2. Expanding applications of CTCs
    • 3.2.1.3. Growing demand for early and rapid cancer diagnosis
    • 3.2.1.4. Growing incidence of cancer
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Consistency-related challenges in CTC detection and enrichment
    • 3.2.2.2. Higher preference for Point-of-Care (POC) testing and nonavailability of POC adaptable CTC tests
    • 3.2.2.3. Lower applicability of CTCs in rare cancers
• 3.3. Circulating Tumor Cells Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Circulating Tumor Cells Market: Technology Estimates & Trend Analysis

• 4.1. Technology Segment Dashboard
• 4.2. Global Circulating Tumor Cells Market Technology Movement Analysis
• 4.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. CTC Detection & Enrichment Methods
    • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.2. Immunocapture (Label-based)
      • 4.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2.2. Positive Selection
        • 4.4.1.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.2.3. Negative Selection
        • 4.4.1.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.3. Size-based Separation (Label-free)
      • 4.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3.2. Membrane-based
        • 4.4.1.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
      • 4.4.1.3.3. Microfluidic-based
        • 4.4.1.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.4. Density-based Separation (Label-free)
      • 4.4.1.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.1.5. Combined Methods
      • 4.4.1.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. CTC Direct Detection Methods
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2.2. SERS
      • 4.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2.3. Microscopy
      • 4.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 4.4.2.4. Others
      • 4.4.2.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. CTC Analysis
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Circulating Tumor Cells Market: Application Estimates & Trend Analysis

• 5.1. Application Segment Dashboard
• 5.2. Global Circulating Tumor Cells Market Application Movement Analysis
• 5.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Clinical
    • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.1.2. Risk Assessment
      • 5.4.1.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.1.3. Screening and Monitoring
      • 5.4.1.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.2. Research
    • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2.2. Cancer Stem Cell & Tumorogenesis Research
      • 5.4.2.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.4.2.3. Drug/Therapy Development
      • 5.4.2.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Circulating Tumor Cells Market: Product Estimates & Trend Analysis

• 6.1. Product Segment Dashboard
• 6.2. Global Circulating Tumor Cells Market Product Movement Analysis
• 6.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Kits & reagents
    • 6.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
  • 6.4.2. Blood collection tubes
    • 6.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4.3. Devices or systems
    • 6.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Circulating Tumor Cells Market: Specimen Estimates & Trend Analysis

• 7.1. Specimen Segment Dashboard
• 7.2. Global Circulating Tumor Cells Market Specimen Movement Analysis
• 7.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by Specimen, 2018 to 2030 (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.4.1. Blood
    • 7.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
  • 7.4.2. Bone marrow
    • 7.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4.3. Other body fluids
    • 7.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Circulating Tumor Cells Market: End Use Estimates & Trend Analysis

• 8.1. End Use Segment Dashboard
• 8.2. Global Circulating Tumor Cells Market End Use Movement Analysis
• 8.3. Global Circulating Tumor Cells Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.4.1. Research and academic institutes
    • 8.4.1.1. Market estimates and forecasts 2018 - 2030 (USD million)
  • 8.4.2. Hospital and clinics
    • 8.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.4.3. Diagnostic centers
    • 8.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Circulating Tumor Cells Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2024 & 2030
• 9.2. Regional Market Dashboard
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.1.5. Target disease prevalence
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.2.5. Target disease prevalence
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.3.5. Target disease prevalence
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.1.5. Target disease prevalence
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.2.5. Target disease prevalence
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.3.5. Target disease prevalence
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.4.5. Target disease prevalence
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.5.5. Target disease prevalence
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.6.5. Target disease prevalence
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.7.5. Target disease prevalence
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.8.5. Target disease prevalence
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.1.5. Target disease prevalence
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.2.5. Target disease prevalence
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.3.5. Target disease prevalence
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.4.5. Target disease prevalence
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.5.5. Target disease prevalence
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.6.5. Target disease prevalence
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.6.1.5. Target disease prevalence
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.6.2.5. Target disease prevalence
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.1.5. Target disease prevalence
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.2.5. Target disease prevalence
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.3.5. Target disease prevalence
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.4.5. Target disease prevalence

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis, By Key Market Participants
• 10.2. Company/Competition Categorization
• 10.3. Vendor Landscape
  • 10.3.1. List of key distributors and channel partners
  • 10.3.2. Key customers
  • 10.3.3. Key company position analysis, 2024
  • 10.3.4. QIAGEN
    • 10.3.4.1. Company overview
    • 10.3.4.2. Financial performance
    • 10.3.4.3. Product benchmarking
    • 10.3.4.4. Strategic initiatives
  • 10.3.5. Bio-Techne Corp.
    • 10.3.5.1. Company overview
    • 10.3.5.2. Financial performance
    • 10.3.5.3. Product benchmarking
    • 10.3.5.4. Strategic initiatives
  • 10.3.6. Precision Medicine Group, LLC.
    • 10.3.6.1. Company overview
    • 10.3.6.2. Financial performance
    • 10.3.6.3. Product benchmarking
    • 10.3.6.4. Strategic initiatives
  • 10.3.7. Bio-Rad Laboratories, Inc.
    • 10.3.7.1. Company overview
    • 10.3.7.2. Financial performance
    • 10.3.7.3. Product benchmarking
    • 10.3.7.4. Strategic initiatives
  • 10.3.8. Natera, Inc.
    • 10.3.8.1. Company overview
    • 10.3.8.2. Financial performance
    • 10.3.8.3. Product benchmarking
    • 10.3.8.4. Strategic initiatives
  • 10.3.9. Illumina, Inc.
    • 10.3.9.1. Company overview
    • 10.3.9.2. Financial performance
    • 10.3.9.3. Product benchmarking
    • 10.3.9.4. Strategic initiatives
  • 10.3.10. Cell Microsystems
    • 10.3.10.1. Company overview
    • 10.3.10.2. Financial performance
    • 10.3.10.3. Product benchmarking
    • 10.3.10.4. Strategic initiatives
  • 10.3.11. Greiner Bio One International GmbH
    • 10.3.11.1. Company overview
    • 10.3.11.2. Financial performance
    • 10.3.11.3. Product benchmarking
    • 10.3.11.4. Strategic initiatives
  • 10.3.12. Ikonisys Inc.
    • 10.3.12.1. Company overview
    • 10.3.12.2. Financial performance
    • 10.3.12.3. Product benchmarking
    • 10.3.12.4. Strategic initiatives
  • 10.3.13. Miltenyi Biotec
    • 10.3.13.1. Company overview
    • 10.3.13.2. Financial performance
    • 10.3.13.3. Product benchmarking
    • 10.3.13.4. Strategic initiatives
  • 10.3.14. Creative Bioarray
    • 10.3.14.1. Company overview
    • 10.3.14.2. Financial performance
    • 10.3.14.3. Product benchmarking
    • 10.3.14.4. Strategic initiatives
  • 10.3.15. BioFluidica
    • 10.3.15.1. Company overview
    • 10.3.15.2. Financial performance
    • 10.3.15.3. Product benchmarking
    • 10.3.15.4. Strategic initiatives
  • 10.3.16. Abnova Corporation
    • 10.3.16.1. Company overview
    • 10.3.16.2. Financial performance
    • 10.3.16.3. Product benchmarking
    • 10.3.16.4. Strategic initiatives
  • 10.3.17. Biolidics Limited
    • 10.3.17.1. Company overview
    • 10.3.17.2. Financial performance
    • 10.3.17.3. Product benchmarking
    • 10.3.17.4. Strategic initiatives
  • 10.3.18. Creativ MicroTech, Inc.
    • 10.3.18.1. Company overview
    • 10.3.18.2. Financial performance
    • 10.3.18.3. Product benchmarking
    • 10.3.18.4. Strategic initiatives
  • 10.3.19. LungLife AI
    • 10.3.19.1. Company overview
    • 10.3.19.2. Financial performance
    • 10.3.19.3. Product benchmarking
    • 10.3.19.4. Strategic initiatives
  • 10.3.20. Epic Sciences
    • 10.3.20.1. Company overview
    • 10.3.20.2. Financial performance
    • 10.3.20.3. Product benchmarking
    • 10.3.20.4. Strategic initiatives
  • 10.3.21. Rarecells Diagnostics
    • 10.3.21.1. Company overview
    • 10.3.21.2. Financial performance
    • 10.3.21.3. Product benchmarking
    • 10.3.21.4. Strategic initiatives
  • 10.3.22. ScreenCell
    • 10.3.22.1. Company overview
    • 10.3.22.2. Financial performance
    • 10.3.22.3. Product benchmarking
    • 10.3.22.4. Strategic initiatives
  • 10.3.23. Menarini Silicon Biosystems
    • 10.3.23.1. Company overview
    • 10.3.23.2. Financial performance
    • 10.3.23.3. Product benchmarking
    • 10.3.23.4. Strategic initiatives
  • 10.3.24. APPLIED DNA SCIENCES, INC.
    • 10.3.24.1. Company overview
    • 10.3.24.2. Financial performance
    • 10.3.24.3. Product benchmarking
    • 10.3.24.4. Strategic initiatives
  • 10.3.25. Sysmex Corporation
    • 10.3.25.1. Company overview
    • 10.3.25.2. Financial performance
    • 10.3.25.3. Product benchmarking
    • 10.3.25.4. Strategic initiatives
  • 10.3.26. STEMCELL Technologies, Inc.
    • 10.3.26.1. Company overview
    • 10.3.26.2. Financial performance
    • 10.3.26.3. Product benchmarking
    • 10.3.26.4. Strategic initiatives